01 octubre 2015

JOURNAL OF VASCULAR SURGERY. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis

Anat Rabinovich, MD, Jacqueline M. Cohen, PhD, Mary Cushman, MD, Susan R. Kahn, MD, MS for the BioSOX Investigators

Objective: Inflammation may play a role in pathogenesis of venous thromboembolism, but the nature of this relationship is not yet understood. The objective of this study was to assess whether inflammation marker levels measured at diagnosis of deep venous thrombosis (DVT) and change in levels during the first month after DVT are associated with anatomic extent of DVT and severity of venous signs and symptoms at baseline and 1 month.

01 octubre 2015

JOURNAL OF VASCULAR SURGERY. Morphologic changes in the vein after different numbers of radiofrequency ablation cycles

Evgeny V. Shaidakov, MD, PhD, Arsen G. Grigoryan, MD, Dmitriy E. Korzhevskii, MD, PhD, Evgeny A. Ilyukhin, MD, Dmitriy A. Rosukhovski, MD, Vasiliy L. Bulatov, MD, Oleg I. Tsarev, MD, PhD

Objective: It has not yet been clarified whether it is possible to decrease the percentage of recurrences after radiofrequency (RF) ablation by way of increasing the number of RF ablation cycles. The aim of this study was to assess the morphologic changes in excised vein fragments after different durations of RF ablation exposure.

01 octubre 2015

JOURNAL OF VASCULAR SURGERY. Complications with office-based venoplasties and stenting and their clinical correlation

Arkady Ganelin, MD, Anil Hingorani, MD, Enrico Ascher, MD, Borislav Kheyson, MD, Eleanora Iadgarova, RN, Natalie Marks, MD, Yuriy Ostrozhynskyy

Background: Endovenous therapy by venoplasty and stenting is rapidly gaining momentum and popularity in treatment of chronic venous insufficiency (nonthrombotic iliac vein lesions, in particular). The purpose of this study was to examine the results of office-based venoplasty and stenting procedures that were performed at our office-based facility from July 28, 2012, until April 28, 2013. The study focused on any complications during and after the procedure.

01 octubre 2015

JOURNAL OF VASCULAR SURGERY. Technical considerations, outcomes, and durability of inferior vena cava stenting

Javairiah Fatima, MD, AbdulAziz AlGaby, MD, James Bena, Mohammad N. Abbasi, MD, Daniel G. Clair, MD

Objective: Inferior vena cava (IVC) thrombosis is an uncommon condition but can cause devastating complications to those affected. Historically, this has been treated with an open surgical approach (with high morbidity) and with angioplasty in more recent years. Herein we describe technical aspects of stenting of the IVC in patients with recalcitrant chronic occlusive disease and evaluate its outcomes.

01 octubre 2015

JOURNAL OF VASCULAR SURGERY. Treatment of nutcracker syndrome with open and endovascular interventions

Young Erben, MD, Peter Gloviczki, MD, Manju Kalra, MBBS, Haraldur Bjarnason, MD, Nanette R. Reed, MD, Audra A. Duncan, MD, Gustavo S. Oderich, MD, Thomas C. Bower, MD

Objective: Nutcracker syndrome (NS) is a rare cause of hematuria, flank pain, and renal venous hypertension due to compression of the left renal vein (LRV) between the aorta and the superior mesenteric artery. To evaluate outcomes of open surgery and endovascular interventions, we reviewed our experience.

01 noviembre 2015

JOURNAL OF VASCULAR SURGERY. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease

Yiu Che Chan, MBBS, MD, FRCS, Stephen W. Cheng, MBBS, MS, FRCS, Grace C. Cheung, MMedSc

Background: The femoropopliteal arteries are subjected to considerable axial and bending deformity due to flexion at the hip and knee joints. The Supera helical interwoven nitinol stent system (IDEV Technologies, Inc/Abbott Laboratories, Inc, Webster, Tex) has good conformability and flexibility, with a very low incidence of mechanical fatigue. This study reviewed our experience with the use of Supera stents for femoropopliteal atherosclerotic lesions and identified risk factors for restenosis or occlusion.

01 septiembre 2015

JACC. Predictors of Catastrophic Adverse Outcomes in Children With Pulmonary Hypertension Undergoing Cardiac Catheterization. A Multi-Institutional Analysis From the Pediatric Health Information Systems Database

Michael L. O’Byrne, MD, MSCE∗,†; Andrew C. Glatz, MD, MSCE∗,†; Brian D. Hanna, MD, PhD∗; Russell T. Shinohara, PhD†; Matthew J. Gillespie, MD∗; Yoav Dori, MD, PhD∗; Jonathan J. Rome, MD∗; Steven M. Kawut, MD†,‡,§

Background: Cardiac catheterization is the standard of care procedure for diagnosis, choice of therapy, and longitudinal follow-up of children and adults with pulmonary hypertension (PH). However, the procedure is invasive and has risks associated with both the procedure and recovery period.

01 septiembre 2015

JACC. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease. Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery

Sripal Bangalore, MD, MHA∗; Yu Guo, MA∗; Zaza Samadashvili, MD†; Saul Blecker, MD, MHS∗; Jinfeng Xu, PhD∗; Edward L. Hannan, PhD, MS†

Background: Randomized trials of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) routinely exclude patients with chronic kidney disease (CKD).

01 septiembre 2015

JACC. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting

Arun K. Thukkani, MD, PhD∗,†; Kush Agrawal, MD∗,‡; Lillian Prince, MS§; Kyle J. Smoot, MA§; Alyssa B. Dufour, PhD§,‖; Kelly Cho, MPH, PhD§; David R. Gagnon, MD, PhD§; Galina Sokolovskaya, MS§; Samantha Ly, MA∗; Sara Temiyasathit, PhD∗; David P. Faxon, MD∗,†,¶; J. Michael Gaziano, MD, PhD∗,†,§,¶; Scott Kinlay, MBBS, PhD∗,†,¶

Background: Recent large clinical trials show lower rates of late cardiovascular events by extending clopidogrel >12 months after percutaneous coronary revascularization (PCI). However, concerns of increased bleeding have elicited support for limiting prolonged treatment to high-risk patients.

01 septiembre 2015

JACC. Initial Experience of Transcatheter Mitral Valve Replacement With a Novel Transcatheter Mitral Valve. Procedural and 6-Month Follow-Up Results

Omar Abdul-Jawad Altisent, MD; Eric Dumont, MD; François Dagenais, MD; Mario Sénéchal, MD; Mathieu Bernier, MD; Kim O’Connor, MD; Silvie Bilodeau, MD; Jean Michel Paradis, MD; Francisco Campelo-Parada, MD; Rishi Puri, MBBS, PhD; Maria del Trigo, MD; Josep Rodés-Cabau, MD

Background: There are scarce data available on transcatheter mitral valve replacement (TMVR), and these have been limited to procedural results, with no follow-up status reported.

01 septiembre 2015

JACC. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention

Philippe Généreux, MD∗,†,‡; Gennaro Giustino, MD§; Bernhard Witzenbichler, MD‖; Giora Weisz, MD∗,†,¶; Thomas D. Stuckey, MD#; Michael J. Rinaldi, MD∗∗; Franz-Josef Neumann, MD††; D. Christopher Metzger, MD‡‡; Timothy D. Henry, MD§§,‖‖; David A. Cox, MD¶¶; Peter L. Duffy, MD, MMM##; Ernest Mazzaferri, MD∗∗∗; Mayank Yadav, MD∗; Dominic P. Francese, MPH∗; Tullio Palmerini, MD†††; Ajay J. Kirtane, MD, SM∗,†; Claire Litherland, MS∗; Roxana Mehran, MD∗,§; Gregg W. Stone, MD∗,†

Background: The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation are unclear.

01 agosto 2015

JACC. Physiological Growth, Remodeling Potential, and Preserved Function of a Novel Bioprosthetic Tricuspid Valve. Tubular Bioprosthesis Made of Small Intestinal Submucosa-Derived Extracellular Matrix

Farhan Zafar, MD∗; Robert B. Hinton, MD†; Ryan A. Moore, MD†; R. Scott Baker, BS∗; Roosevelt Bryant, III, MD∗; Daria A. Narmoneva, PhD‡; Michael D. Taylor, MD, PhD†; David L. Morales, MD∗

Background: Prosthetic valves currently used in children lack the ability to grow with the patient and often require multiple reoperations. Small intestinal submucosa-derived extracellular matrix (SIS-ECM) has been used successfully as a patch for repair in various tissues, including vessels, valves, and myocardium.

01 agosto 2015

JACC. 1-Year Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves. Results From the CHOICE Randomized Clinical Trial

Mohamed Abdel-Wahab, MD∗; Franz-Josef Neumann, MD†; Julinda Mehilli, MD‡; Christian Frerker, MD§; Doreen Richardt, MD‖; Martin Landt, MD∗; John Jose, MD∗; Ralph Toelg, MD∗; Karl-Heinz Kuck, MD§; Steffen Massberg, MD‡; Derek R. Robinson, DPhil¶; Mohamed El-Mawardy, MD∗; Gert Richardt, MD∗

Background: The use of a balloon-expandable transcatheter heart valve previously resulted in a greater rate of device success compared with a self-expandable transcatheter heart valve.

01 agosto 2015

JACC. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. Insights From the APPRAISE-2 Trial

Connie N. Hess, MD, MHS∗; Stefan James, MD, PhD†; Renato D. Lopes, MD, PhD∗; Daniel M. Wojdyla, MSc∗; Megan L. Neely, PhD∗; Danny Liaw, MD, PhD‡; Emil Hagstrom, MD, PhD∗; Deepak L. Bhatt, MD, MPH§; Steen Husted, MD, DSc‖; Shaun G. Goodman, MD, MSc¶; Basil S. Lewis, MD#; Freek W.A. Verheugt, MD∗∗; Raffaele De Caterina, MD, PhD††; Hisao Ogawa, MD‡‡; Lars Wallentin, MD, PhD†; John H. Alexander, MD, MHS∗

Background: Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS).

01 agosto 2015

JACC. 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve Replacement. Results From the Italian OBSERVANT Study

Corrado Tamburino, MD∗,†; Marco Barbanti, MD∗,†; Paola D’Errigo, RS‡; Marco Ranucci, MD§; Francesco Onorati, MD‖; Remo Daniel Covello, MD¶; Francesco Santini, MD#; Stefano Rosato, RS§; Gennaro Santoro, MD∗∗; Danilo Fusco, RS††; Claudio Grossi, MD‡‡; Fulvia Seccareccia, RS‡

Background: There is a paucity of prospective and controlled data on the comparative effectiveness of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in a real-world setting.